Other examples of beneficial targeting of Notch1 and Notch3 signaling for affecting CSC population and tumor sensitization to cisplatin treatment have been demonstrated in preclinical models of gastric cancer, neuroblastoma, hepatocellular carcinoma, renal cell carcinoma, cervical cancer, and nasopharyngeal carcinoma [431,432,433,434,435,436,437]. The gene discussed is NOTCH3; the disease is hepatocellular carcinoma.